Overview: Why toxicity matters in multispecific antibodies and immune-cell engagers
The ESMO Therapeutic Landscapes webinar series returns in 2026 with a focused session on the toxicity profiles of next-generation biologics. Multispecific antibodies and immune-cell engagers represent a rapidly advancing frontier in cancer therapy, offering the promise of simultaneous targeting of tumor antigens and immune cells. However, their complexity also introduces unique safety considerations, including cytokine release syndrome, neurotoxicity, on-target off-tumor effects, and inflammatory adverse events. This webinar is designed for oncologists, clinical researchers, and healthcare professionals who monitor, manage, and study these agents in real-world and trial settings.
Key topics: safety profiles of multispecifics and immune-cell engagers
Attendees will explore how structural design, binding valency, and target selection influence toxicity. The session covers:
- Mechanisms of immune activation and potential off-target effects
- Patterns and grading of adverse events associated with multispecifics
- Strategies to mitigate toxicity without compromising efficacy
- Early detection methods, monitoring schedules, and risk mitigation planning
- Management algorithms for common toxicities such as cytokine release syndrome, neurotoxicity, and hepatotoxicity
Clinical management: translating safety data into practice
The session emphasizes practical approaches to safety and patient care. Clinicians will review best practices for dose optimization, premedication regimens, and escalation plans. Case-based discussions highlight decision-making scenarios in which balancing tumor control with tolerability is critical. Insights into patient selection criteria, biomarker-driven risk assessment, and real-world experiences help attendees translate trial data into everyday practice.
Why this webinar matters now
As multispecific antibodies and immune-cell engagers move closer to routine use, robust safety frameworks are essential. Regulatory expectations increasingly rely on comprehensive toxicity profiling, proactive monitoring, and clear management pathways. This webinar provides a practical blueprint for clinicians and researchers to anticipate, identify, and respond to adverse events, ultimately improving patient outcomes in oncology.
Who should participate
This program is tailored for oncologists, hematologists, clinical researchers, nurse practitioners, physician assistants, pharmacists, and healthcare professionals involved in the development, delivery, and oversight of next-generation biologics. Those working in pharma, academia, and hospital settings will benefit from a structured exploration of toxicity patterns and management strategies.
What to expect: format and takeaways
Expect expert-led presentations, interactive discussions, and practical guidelines that attendees can apply in clinical trials and routine care. The session will summarize emerging safety signals, propose standardized monitoring approaches, and provide a framework for communicating risk with patients and care teams.
